Challenges in the development of new therapies for bronchiectasis

Bibliography

• Bilton D, Loebinger MR, Wilson R. Non-cystic fibrosis bronchiectasis: an evidence-based for new therapies. Lancet Respir Med 2014;2(12):958-60
   PubMedGoogle Scholar
• Seitz AE, Olivier KN, Adjemian J, et al. Trends in bronchiectasis among medicare beneficiaries in the United States, 2000 to 2007. Chest 2012;142:432-9
   PubMed Web of Science ®Google Scholar
• Ringshausen FC, de Roux A, Pletz MW, et al. Bronchiectasis-associated hospitalizations in Germany, 2005-2011: a population-based study of disease burden and trends. PLoS One 2013;8(8):e71109
   PubMed Web of Science ®Google Scholar
• Martinez-Garcia MA, Soler-Cataluna JJ, Donat Sanz Y, et al. Factors associated with bronchiectasis in patients with COPD. Chest 2011;140(5):1130-7
   PubMed Web of Science ®Google Scholar
• Joish VN, Spilsbury-Cantalupo M, Operschall E, et al. Economic burden of non-cystic fibrosis bronchiectasis in the first year after diagnosis from a US health plan perspective. Appl Health Econ Health Policy 2013;11(3):299-304
   PubMedGoogle Scholar
• Goeminne PC, Nawrot TS, Ruttens D, et al. Mortality in non-cystic fibrosis bronchiectasis: a prospective cohort analysis. Respir Med 2014;108(2):287-96
   PubMed Web of Science ®Google Scholar
• Kelly MG, Murphy S, Elborn JS. Bronchiectasis in secondary care: a comprehensive profile of a neglected disease. Eur J Intern Med 2003;14(8):488-92
   PubMedGoogle Scholar
• Chalmers JD, Goemmine PC, Aliberti S, et al. The Bronchiectasis Severity Index: an international derivation and validation study. Am J Respir Crit Care Med 2014;189(5):576-85
   PubMed Web of Science ®Google Scholar
• Gao Y, Guan W, Xu G, et al. Sleep disturbances and health-related quality of life in adults with steady-state bronchiectasis. PLoS One 2014;9(7):e102970
   Google Scholar
• Chalmers JD, McHugh BJ, Doherty CJ, et al. Mannose binding lectin deficiency and disease severity in non-CF bronchiectasis: a prospective study. Lancet Respir Med 2013;1(3):175-274
   PubMed Web of Science ®Google Scholar
• Chan SL, Chan-Yeung MM, Ooi GC, et al. Validation of the Hong Kong Chinese version of the St. George Respiratory Questionnaire in patients with bronchiectasis. Chest 2002;122(6):2030-7
   PubMed Web of Science ®Google Scholar
• Stockley R, De Soyza A, Gunawardena K, et al. Phase II study of a neutrophil elastase inhibitor (AZD9668) in patients with bronchiectasis. Respir Med 2013;107(4):524-33
   PubMed Web of Science ®Google Scholar
• Kupczyk M, ten Brinke A, Sterk PJ, et al. Frequent exacerbators – a distinct phenotype of severe asthma. Clin Exp Allergy 2014;44(2):212-21
   PubMed Web of Science ®Google Scholar
• Wedzicha JA, Singh D, Vestbo J, et al. Extrafine beclomethasone/formoterol in severe COPD patients with history of exacerbations. Respir Med 2014;108(8):1153-62
   PubMed Web of Science ®Google Scholar
• Agusti A, de Teresa L, De Backer W, et al. A comparison of the efficacy and safety of once-daily fluticasone furoate/vilaterol with twice-daily fluticasone propionate/salmeterol in moderate to very severe COPD. Eur Respir J 2014;43(3):763-72
   PubMed Web of Science ®Google Scholar
• Han MK, Swigris J, Liu L, et al. Gender influences health-related quality of life in IPF. Respir Med 2010;104(5):724-30
   PubMedGoogle Scholar
• Loebinger MR, Wells AU, Hansell DM, et al. Mortality in bronchiectasis: a long-term study assessing the factors influencing survival. Eur Respir J 2009;34(4):843-9
   PubMed Web of Science ®Google Scholar
• Roberts HJ, Hubbard R. Trends in bronchiectasis mortality in England and Wales. Respir Med 2010;104(7):981-5
   PubMed Web of Science ®Google Scholar
• Cole PJ. Inflammation: a two-edged sword--the model of bronchiectasis. Eur J Respir Dis Suppl 1986;147:6-15
   PubMedGoogle Scholar
• Chalmers JD. Bronchiectasis trials: losing the battle but winning the war? Lancet Respir Med 2014;2(9):679-81
   PubMedGoogle Scholar
• Doring G, Flume P, Heijerman H, Elborn JS. Treatment of lung infection in patients with cystic fibrosis: current and future strategies. J Cyst Fibros 2012;11:461-79
   PubMed Web of Science ®Google Scholar
• Stockley RA, Hill SL, Burnett D. Nebulized amoxicillin in chronic purulent bronchiectasis. Clin Ther 1985;7:593-9
   PubMed Web of Science ®Google Scholar
• Barker AF, Couch L, Fiel SB, et al. Tobramycin solution for inhalation reduces sputum Pseudomonas aeruginosa density in bronchiectasis. Am J Respir Crit Care Med 2000;162:481-5
   PubMed Web of Science ®Google Scholar
• Drobnic ME, Sune P, Montoro JB, et al. Inhaled tobramycin in non-cystic fibrosis with chronic and chronic bronchial infection with Pseudomonas aeruginosa. Ann Pharmacother 2005;39(1):39-44
   PubMed Web of Science ®Google Scholar
• Scheinberg P, Shore E. A pilot study of the safety and efficacy of tobramycin solution for inhalation in patients with severe bronchiectasis. Chest 2005;127(4):1420-6
   PubMed Web of Science ®Google Scholar
• Haworth CS, Foweraker JE, Wilkinson P, et al. Inhaled colistin in patients with bronchiectasis and chronic pseudomonas aeruginosa infection. Am J Respir Crit Care Med 2014;189(8):975-82
   PubMed Web of Science ®Google Scholar
• Available from: http://www.isrctn.com/ISRCTN49790596 [Accessed 20 December 2014]
   Google Scholar
• McCoy KS, Quittner AL, Oermann CM, et al. Inhaled aztreonam lysine for chronic airway Pseudomonas aeruginosa in cystic fibrosis. Am J Respir Crit Care Med 2008;178:921-8
   PubMed Web of Science ®Google Scholar
• Barker AF, O’Donnell AE, Flume P, et al. Aztreonam for inhalation solution in patients with non-cystic fibrosis bronchiectasis (AIR-BX1 and AIR-BX2): two randomised double-blind, placebo-controlled phase 3 trials. Lancet Respir Med 2014;2(9):738-49
   PubMed Web of Science ®Google Scholar
• Murray MP, Govan JRW, Docherty CJ, et al. A randomised controlled trial of nebulised gentamicin in non-cystic fibrosis bronchiectasis. Am J Respir Crit Care Med 2011;183(4):491-9
   PubMed Web of Science ®Google Scholar
• Wilson R, Welte T, Polverino E, et al. Ciprofloxacin dry powder for inhalation in non-cystic fibrosis bronchiectasis: a phase II randomised study. Eur Respir J 2013;41(5):1108-15
   Google Scholar
• Serisier DJ, Bilton D, De Soyza A, et al. Inhaled, dual release liposomal ciprofloxacin in non-cystic fibrosis bronchiectasis (ORBIT-2): a randomised, double-blind, placebo-controlled trial. Thorax 2013;68(9):812-17
   PubMed Web of Science ®Google Scholar
• Bilton D, Henig N, Morrissey B, Gottfried M. Addition of inhaled tobramycin to ciprofloxacin for acute exacerbations of Pseudomonas aeruginosa in adult bronchiectasis. Chest 2006;130(5):1503-10
   PubMed Web of Science ®Google Scholar
• Wong C, Jayaram L, Karalus N, et al. Azithromycin for prevention of exacerbations in non-cystic fibrosis bronchiectasis (EMBRACE): a randomised, double-blind, placebo-controlled trial. Lancet 2012;380(9842):660-7
   PubMed Web of Science ®Google Scholar
• Altenburg J, de Graaff CS, Stienstra Y, et al. Effect of azithromycin maintenance treatment on infectious exacerbations among patients with non-cystic fibrosis bronchiectasis: the BAT randomized controlled trial. JAMA 2013;309:1251-9
   PubMed Web of Science ®Google Scholar
• Serisier DJ, Martin ML, McGuckin MA, et al. Effect of long-term, low-dose erythromycin on pulmonary exacerbations among patients with non-cystic fibrosis bronchiectasis: the BLESS randomized controlled trial. JAMA 2013;309:1260-7
   PubMed Web of Science ®Google Scholar
• Wu Q, Shen W, Cheng H, Zhou X. Long-term macrolides for non-cystic fibrosis bronchiectasis: a systematic review and meta-analysis. Respirology 2014;19(3):321-9
   PubMed Web of Science ®Google Scholar
• McCullough AR, Tunney MM, Elborn JS, et al. Treatment adherence and health outcomes in patients with bronchiectasis. BMC Pulm Med 2014;14:107
   PubMed Web of Science ®Google Scholar
• Haworth CS, Bilton D, Elborn JS. Long-term macrolide maintenance therapy in non-CF bronchiectasis: evidence and questions. Respir Med 2014;108(10):1397-408
   PubMed Web of Science ®Google Scholar
• Ray WA, Murray KT, Hall K, et al. Azithromycin and the risk of cardiovascular death. N Engl J Med 2012;366(20):1881-90
   PubMed Web of Science ®Google Scholar
• Martinez-Garcia MA, Soler-Cataluna JJ, Catalan-Serra P, et al. Clinical efficacy and safety of budesonide-formoterol in non-cystic fibrosis bronchiectasis. Chest 2012;141(2):461-8
   PubMed Web of Science ®Google Scholar
• Kapur N, Bell S, Kolbe J, Chang AB. Inhaled steroids for bronchiectasis. Cochrane Database Syst Rev 2009(1):CD000996
   Google Scholar
• Singanayagam A, Chalmers JD, Akram AR, Hill AT. Impact of inhaled corticosteroid use on outcome in COPD patients admitted with pneumonia. Eur Respir J 2011;38(1):36-41
   PubMed Web of Science ®Google Scholar
• Andrejak C, Nielson R, Thomson VO, et al. Chronic respiratory disease, inhaled corticosteroids and risk of non-tuberculous mycobacteriosis. Thorax 2013;68(3):256-62
   PubMed Web of Science ®Google Scholar
• Pasteur MC, Bilton D, Hill AT. British Thoracic Society guideline for non-CF bronchiectasis. Thorax 2010;65(Suppl 1):i1-58
   PubMed Web of Science ®Google Scholar
• Chalmers JD, Hill AT. Mechanisms of immune dysfunction and bacterial persistence in non-cystic fibrosis bronchiectasis. Mol Immunol 2013;55:27-34
   PubMed Web of Science ®Google Scholar
• Pavord I, De Soyza A, Elborn JS, et al. Efficacy and safety of AZD5069, a CXCR2 antagonist in adult bronchiectasis. Eur Respir J 2013;42(Suppl 57):P1593
   Google Scholar
• Konstan MW, Doring G, Heltsche SL, et al. A randomized double blind, placebo controlled phase 2 trial of BIIL284BS (an LTB4 receptor antagonist) for the treatment of lung disease in children and adults with cystic fibrosis. J Cyst Fibros 2014;13(2):148-55
   PubMed Web of Science ®Google Scholar
• Doring G, Bragonzi A, Paroni M, et al. BIL 284 reduces neutrophil numbers but increases P. aeruginosa bacteremia and inflammation in mouse lungs. J Cyst Fibros 2014;13(2):156-63
   PubMed Web of Science ®Google Scholar
• Rennard SI, Fogarty C, Kelsen S, et al. The safety and efficacy of infliximab in moderate to severe chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2007;175(9):926-34
   PubMed Web of Science ®Google Scholar
• Aitkey ML, Bellon G, De Boeck K, et al. Long-term inhaled dry powder mannitol in cystic fibrosis: an international randomized study. Am J Respir Crit Care Med 2012;185(6):645-52
   PubMedGoogle Scholar
• Bilton D, Bellon G, Charlton B, et al. Pooled analysis of two large randomised phase III inhaled mannitol studies in cystic fibrosis. J Cyst Fibros 2013;12(4):367-76
   PubMed Web of Science ®Google Scholar
• Bilton D, Daviskas E, Anderson SD, et al. Phase 3 randomized study of the efficacy and safety of inhaled dry powder mannitol for the symptomatic treatment of non-cystic fibrosis bronchiectasis. Chest 2013;144(1):215-25
   PubMed Web of Science ®Google Scholar
• Bilton D, Tino G, Barker AF, et al. Inhaled mannitol for non-cystic fibrosis bronchiectasis: a randomised, controlled trial. Thorax 2014;69(12):1073-9
   PubMed Web of Science ®Google Scholar
• Nicolson CH, Stirling RG, Borg BM, et al. The long term effect of inhaled hypertonic saline 6% in non-cystic fibrosis bronchiectasis. Respir Med 2012;106(5):661-7
   PubMed Web of Science ®Google Scholar
• O’Donnell AE, Barker AF, Ilowite JS, Fick RB. Treatment of idiopathic bronchiectasis with aerosolized recombinant human DNase I. rhDNase Study Group. Chest 1998;113:1329-34
   PubMed Web of Science ®Google Scholar
• Young RL, Malcolm KC, Kret JE, et al. Neutrophil extracellular trap (NET)-mediated killing of Pseudomonas aeruginosa: evidence of acquired resistance within the CF airway, independent of CFTR. PLoS One 2011;6(9):e23637
   PubMed Web of Science ®Google Scholar
• Dubois AV, Gauthier A, Brea D, et al. Influence of DNA on the activities and inhibition of neutrophil serine proteases in cystic fibrosis sputum. Am J Respir Cell Mol Biol 2012;47(1):80-6
   PubMed Web of Science ®Google Scholar
• Hill AT, Welham S, Reid K, Bucknall CE. British Thoracic Society national bronchiectasis audit 2010 and 2011. Thorax 2012;67(10):928-30
   PubMedGoogle Scholar
• Paganin F, Seneterre E, Chanez P, et al. Computed tomography of the lungs in asthma: influence of disease severity and etiology. Am J Respir Crit Care Med 1996;153:110-14
   PubMed Web of Science ®Google Scholar
• Blasi F, Chalmers JD, Aliberti S. COPD and Bronchiectasis: phenotype, endotype or co-morbidity? COPD 2014;11(6):603-4
   PubMedGoogle Scholar
• Swinson DR, Symmons D, Suresh U, et al. Decreased survival in patients with co-existent rheumatoid arthritis and bronchiectasis. Br J Rheumatol 1997;36(6):689-91
   PubMedGoogle Scholar
• Griffin DE. Nontuberculous mycobacterial lung disease. Curr Opin Infect Dis 2010;23(2):185-90
   PubMedGoogle Scholar
• McShane PJ, Naureckas ET, Strek ME. Bronchiectasis in a diverse US population: effects of ethnicity on etiology and sputum culture. Chest 2012;142(1):159-67
   PubMedGoogle Scholar
• Redding GJ, Singleton RJ, Valery PC, et al. Respiratory exacerbations in indigenous children from two countries with non-cystic fibrosis chronic suppurative lung disease/bronchiectasis. Chest 2014;146(3):762-74
   PubMed Web of Science ®Google Scholar
• Martinez Garcia MA, de Gracia J, Vendrell Relat M, et al. Multidimensional approach to non-cystic fibrosis bronchiectasis; the FACED score. Eur Respir J 2014;43(5):1357-67
   PubMedGoogle Scholar
• Nick JA, Moskowitz SM, Chmiel JF, et al. Azithromycin may antagonize inhaled tobramycin when targeting Pseudomonas aeruginosa in cystic fibrosis. Ann Am Thorac Soc 2014;11(3):342-50
   PubMedGoogle Scholar
• Chang AB, Bell SC, Torzillo PJ, et al. Chronic suppurative lung disease and bronchiectasis in children and adults in Australia and New Zealand Thoracic Society of Australia and New Zealand guidelines. Med J Aust 2015;202(1):21-3
   PubMed Web of Science ®Google Scholar
• Murray MP, Turnbull K, Macquarrie S, Hill AT. Assessing response to treatment of exacerbations of bronchiectasis in adults. Eur Respir J 2009;33(2):312-18
   PubMed Web of Science ®Google Scholar
• Langsetmo L, Platt RW, Ernst P, Bourbeau J. Underreporting exacerbation of chronic obstructive pulmonary disease in a longitudinal cohort. Am J Respir Crit Care Med 2008;177(4):396-401
   PubMed Web of Science ®Google Scholar
• Wilson CB, Jones PW, O’Leary CJ, et al. Validation of the St. Georges Respiratory Questionnaire in bronchiectasis. Am J Respir Crit Care Med 1997;156(2 Pt 1):536-41
   PubMed Web of Science ®Google Scholar
• Quittner AL, O’Donnell AE, Salathe MA, et al. Quality of life questionnaire-Bronchiectasis: final psychometric analyses and determination of minimal important difference scores. Thorax 2015;70(1):12-20
   PubMed Web of Science ®Google Scholar
• Mandal P, Chalmers JD, Graham C, et al. Atorvastatin as a stable treatment in bronchiectasis: a randomised controlled trial. Lancet Respir Med 2014;2(6):455-63
   PubMed Web of Science ®Google Scholar
• Chalmers JD, Smith MP, McHugh B, et al. Short and long term antibiotic therapy reduces airway and systemic inflammation in non-CF bronchiectasis. Am J Respir Crit Care Med 2012;186(7):657-65
   PubMed Web of Science ®Google Scholar
• Horsley AR, Gustafsson PM, Macleod KA, et al. Lung clearance index is a sensitive, repeatable and practical measure of airways disease in adults with cystic fibrosis. Thorax 2008;63(2):135-40
   PubMed Web of Science ®Google Scholar
• Rowan SA, Bradley JM, Bradbury I, et al. Lung clearance index is a repeatable and sensitive indicator of radiological changes in bronchiectasis. Am J Respir Crit Care Med 2014;189(5):586-92
   PubMedGoogle Scholar
• Gonem S, Scadding A, Soares M, et al. Lung clearance index in adults with non-cystic fibrosis bronchiectasis. Respir Res 2014;15:59
   PubMed Web of Science ®Google Scholar
• Tsang KW, Chan K, Ho P, et al. Sputum elastase in steady-state bronchiectasis. Chest 2000;117(2):420-6
   PubMedGoogle Scholar
• Chalmers JD, McHugh BJ, Doherty CJ, et al. Vitamin-D deficiency is associated with chronic bacterial colonisation and disease severity in non-CF bronchiectasis. Thorax 2012;68(1):39-47
   PubMedGoogle Scholar
• Shoemark A, Devaraj A, Meister M, et al. Elevated peripheral airway nitric oxide in bronchiectasis reflects disease severity. Respir Med 2011;105(6):885-91
   PubMed Web of Science ®Google Scholar
• Loeve M, Krestin GP, Rosenfeld M, et al. Chest computed tomography: a validated surrogate endpoint of cystic fibrosis lung disease? Eur Respir J 2013;42(3):844-57
   PubMed Web of Science ®Google Scholar
• Kuo W, Clet P, Tiddens HA, et al. Monitoring cystic fibrosis lung disease by computed tomography: radiation risk in perspective. Am J Respir Crit Care Med 2014;189(11):1328-36
   PubMed Web of Science ®Google Scholar
• Wielputz MO, Puderbach M, Kopp-Schneider A, et al. Magnetic resonance imaging detects changes in structure and perfusion and response to therapy in early cystic fibrosis lung disease. Am J Respir Crit Care Med 2014;189(8):956-65
   PubMed Web of Science ®Google Scholar
• Tunney MM, Einarsson GG, Wei L, et al. Lung microbiota and bacterial abundance in patients with bronchiectasis when clinically stable and during exacerbation. Am J Respir Crit Care Med 2013;187(10):1118-26
   PubMed Web of Science ®Google Scholar
• Rogers GB, van der Gast CJ, Cuthbertson L, et al. Clinical measures of disease in adult non-CF bronchiectasis correlate with airway microbiota composition. Thorax 2013;68(8):731-7
   PubMed Web of Science ®Google Scholar
• Rogers GB, Bruce KD, Martin ML, et al. The effect of long-term macrolide treatment on respiratory microbiota composition in non-cystic fibrosis bronchiectasis: an analysis from the randomized, double-blind placebo-controlled BLESS trial. Lancet Respir Med 2014;2(12):988-96
   PubMed Web of Science ®Google Scholar
• Available from: www.bronchiectasis.eu [Accessed 20 December 2014]
   Google Scholar
• Aksamit TR, Carretta E, Daley CL, et al. The Bronchiectasis Research Registry: a collaborative research cohort for non-cystic fibrosis bronchiectasis. Am J Respir Crit Care Med 2012;A3654
   Google Scholar
• Ramsey BW, Pepe MS, Quan JM, et al. Intermittent administration of inhaled tobramycin in patients with cystic fibrosis. Cystic Fibrosis Inhaled Tobramycin Study Group. N Engl J Med 1999;340(1):23-30
   PubMed Web of Science ®Google Scholar
• Ramsey BW, Dorkin HC, Eisenberg JD, et al. Efficacy of aerolised tobramycin in patients with cystic fibrosis. N Engl J Med 1993;328:1740-6
   PubMed Web of Science ®Google Scholar
• Clancy JP, Dupont L, Konstan MW, et al. Phase II studies of nebulised Arikace in CF patients with Pseudomonas aeruginosa infection. Thorax 2013;68(9):818-25
   PubMed Web of Science ®Google Scholar
• Available from: https://clinicaltrials.gov/ct2/show/NCT00775138 [Accessed 20 December 2014]
   Google Scholar
• Alothman GA, Ho B, Alsaadi MM, et al. Bronchial constriction and inhaled colistin in cystic fibrosis. Chest 2005;127:522-9
   PubMed Web of Science ®Google Scholar
• Jensen T, Pedersen SS, Garne S, et al. Colistin inhalation therapy in cystic fibrosis patients with chronic Pseudomonas aeruginosa lung infection. J Antimicrob Chemother 1987;19:831-8
   PubMed Web of Science ®Google Scholar
• Saiman L, Marshall BC, Mayer-Hamblett N, et al. Azithromycin in patients with cystic fibrosis chronically infected with Pseudomonas aeruginosa: a randomized controlled trial. JAMA 2003;290(13):1749-56
   PubMed Web of Science ®Google Scholar
• Saiman L, Anstead M, Mayer-Hamblett N, et al. Effect of azithromycin on pulmonary function in patients with cystic fibrosis uninfected with Pseudomonas aeruginosa: a randomized controlled trial. JAMA 2010;303(17):1707-15
   PubMed Web of Science ®Google Scholar
• Fuchs HJ, Borowitz DS, Christiansen DH, et al. Effect of aerosolized recombinant human DNase on exacerbations of respiratory symptoms and on pulmonary function in patients with cystic fibrosis. N Engl J Med 1994;331:637-42
   PubMed Web of Science ®Google Scholar
• Quan JM, Tiddens HA, Sy JP, et al. A two-year randomized, placebo-controlled trial of dornase alfa in young patients with cystic fibrosis with mild lung function abnormalities. J Pediatr 2001;139:813-20
   PubMed Web of Science ®Google Scholar
• Elkins MR, Robinson M, Rose BR, et al. A controlled trial of long term inhaled hypertonic saline in patients with cystic fibrosis. N Engl J Med 2006;354:229-40
   PubMed Web of Science ®Google Scholar
• Donaldson SH, Bennett WD, Zeman KL, et al. Mucus clearance and lung function in cystic fibrosis with hypertonic saline. N Engl J Med 2006;354(3):241-50
   PubMed Web of Science ®Google Scholar